Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 3, 1999, Pages 123-132

  Johnson, Bryon D ^a   Becker, Emily E ^a   Truitt, Robert L ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Donor leukocyte infusion; Graft vs. host disease; Graft vs. leukemia; T subset

Indexed keywords

AKR MOUSE; ALLOTRANSPLANTATION; ANIMAL; ARTICLE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EXPERIMENTAL LEUKEMIA; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; MOUSE; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ANIMALS; BONE MARROW TRANSPLANTATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HISTOCOMPATIBILITY TESTING; INFUSIONS, INTRAVENOUS; LEUKEMIA, EXPERIMENTAL; MICE; MICE, INBRED AKR; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032616043     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1999.v5.pm10392958     Document Type: Article

References (24)

1. Horwitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H, Rimim AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation Blood 75:555-562, 1990.
2. Giralt SA, Champlin RE: Leukemia relapse after allogeneic bone marrow transplantation: a review. Blood 84:3603, 1994.
3. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, Rhee FV, Mittermueller J, Witte TD, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995.
4. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433, 1997.
5. Giralt S, Hester J, Hub Y, Hirsch-Ginsberg C, Rondon G, Seong D, Lee M, Gajewki J, Besien KV, Khouri I, Mebra R, Przepiorka D, Korbling M, Talpaz M, Kantarjian H, Deisseroth A, Champlin R: CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337, 1995.
6. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195, 1996.
7. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329, 1993.
8. Johnson BD, Truitt RL: Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 85:3302, 1995.
9. Truitt RL, Shih CC-Y, LeFever AV: Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma. Transplant 41:301, 1986.
10. Shih CY, Truitt RL. In: Cellular Immunotherapy of Cancer. RL Truitt, RP Gale, MM Bortin, Eds. New York: Alan R. Liss, 1987, p. 439.
11. Taswell C: Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 126:1614, 1981.
12. Johnson BD, Truitt RL: Selective depletion of donor NK cells in vivo decreases graft-vs-host disease without the loss of graft-vs-leukemia reactivity after MHC-matched bone marrow transplantation. Transplant 54:104, 1992.
13. Schreiber KL, Forman J: The effect of chronic GVHD on B cell development. Transplant 55:597, 1993.
14. Truitt RL, LeFever AV, Shih CCY, Jeske JM, Martin TM. In Graft-vs-Host Disease: Immunology, Pathophysiology, and Treatment. SJ Burakoff, HJ Deeg, J Ferrara, K Atkinson, Eds. New York: Marcel Dekker, 1990, p. 177.
15. Blazar BR, Taylor PA, Boyer MW, Panoskaltsis-Mortari A, Allison JP, Vallera DA: CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells. J Immunol 159:3460, 1997.
16. Bunjes D, Theobald M, Hertenstein B, Wiesneth M, Novotny J, Arnold R, Heimpel H: Successful therapy with donor buffy coat transfusions in patients with relapsed chronic myeloid leukemia after bone marrow transplantation is associated with high frequencies of host-reactive interleukin 2-secreting T helper cells. Bone Marrow Transplant 15:713, 1995.
17. Bordignon C, Bonini C, Verzeletti S, Nobili N, Maggioni D, Traversari C, Giavazzi R, Servida P, Zappone E, Benazzi E, Bernardi M, Porta F, Ferrari G, Mavilio F, Rossini S, Blaese RM, Candotti F: Transfer of the HSK-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Human Gene Ther 6:813, 1995.
18. Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, Bordingnon C: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719, 1997.
19. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, O'Reilly RJ: Adoptive immunotherapy using donor leukocytes following bone marrow transplantation for chronic myeloid leukemia: is T cell dose important in determining biological response? Bone Marrow Transplant 15:591, 1995.
20. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Bonlad F, Castro-Malaspina H, Childs BH, Gillio AP, Kernan NA, Small TN, Young JW, O'Reilly RJ: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261, 1995.
21. Champlin R, Jansen J, Ho W, Gajewski J, Nimer S, Lee K, Territo M, Winston D, Tricot G, Reichert T: Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia Transplant Proc 23:1695, 1991.
22. + T-cell-mediated graft-versus-leukemia effect. Leuk Lymphoma 28:33, 1997.
23. Verfaillie CM, Miller WJ, Boylan K, McGlave PB: Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79:1003, 1992.
24. Shlomchik WD, Couzens MS, Tang CB, Emerson SG: Radioresistant host antigen presenting cells are required for acute graft-vs-host disease induction (Abstract). Blood 90:396a, 1997.